Ucl Business Ltd.
52 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
Recorded as renamed to Ucl Ventures Limited (2026)
7
Ending by 2030
Oct 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 16, 2026The maintenance fee for Ultrasound probe (US 11,647,957) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
- 3 fees due Dec 6 to 20, 2026 · next Dec 6
- 2 fees due Jan 4 to 23, 2027 · next Jan 4
- 4 fees due Feb 8 to 27, 2027 · next Feb 8
- 5 fees due Mar 5 to 26, 2027 · next Mar 5
- 4 fees due Apr 10 to 24, 2027 · next Apr 10
- 2 fees due May 19 to 28, 2027 · next May 19
- 2 fees due Jun 10 to 12, 2027 · next Jun 10
- 4 fees due Jul 2 to 9, 2027 · next Jul 2
- 4 fees due Aug 4 to 25, 2027 · next Aug 4
- 6 fees due Sep 3 to 29, 2027 · next Sep 3
- 5 fees due Oct 2 to 30, 2027 · next Oct 2
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,252,851 | Formulations and composites with reactive fillers In force · From the USPTO record | In force | From the USPTO record | |
| US 8,642,072 | Membrane In force · From the USPTO record | In force | From the USPTO record | |
| US 8,889,179 | Membrane In force · From the USPTO record | In force | From the USPTO record | |
| US 8,771,645 | Composition comprising a cell death marker and a wavelength-optimized label In force · From the USPTO record | In force | From the USPTO record | |
| US 9,764,045 | Optimised Coding Sequence and Promoter In force · Medium confidence | In force | Medium confidence | |
| US 10,548,982 | Reversible Covalent Linkage of Functional Molecules In force · High confidence | In force | High confidence | |
| US 10,174,094 | Reversible Covalent Linkage of Functional Molecules In force · Medium confidence | In force | Medium confidence | |
| US 10,709,796 | Optimised Coding Sequence and Promoter In force · Medium confidence | In force | Medium confidence | |
| US 10,478,455 | Therapeutic use of tetrathiomolybdate In force · From the USPTO record | In force | From the USPTO record | |
| US 11,491,127 | Therapeutic Use of Compounds In force · High confidence | In force | High confidence |
Also on record, not counted in the 156: 52 patents in force now held by others · 15 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
91 pending · 28 abandoned · 51 no status recorded